Lumenis Ltd. Reports First Quarter Financial Results

Lumenis Ltd. Reports First Quarter Financial Results  Positive Momentum Continues With 9.5% Revenue Growth, Improved Profitability and Multiple New Product Approvals Across Business Portfolio  YOKNEAM, ISRAEL -- (Marketwired) -- 05/12/14 --  Lumenis Ltd. (NASDAQ: LMNS), the world's largest medical laser company for surgical, ophthalmic and aesthetic applications, today announced first quarter 2014 financial results.  First Quarter 2014 Summary:      --  Revenues of $65.8 million, up 9.5% year-over-year --  Gross Margin of 52.6%, up 151 basis points year-over-year --  Adjusted EBITDA of $4.8 million, up 37.9% year-over-year --  Non-GAAP Net Income of $2.2 million, up 154.0% year-over-year. GAAP     Net Loss of $3.1 million --  $3.1 million net cash flow generated from ongoing business activities     (1)     "We are pleased with our operating performance and financial results, highlighted by strong revenue growth of 9.5% and continued improvement in gross margins and profitability," said Tzipi Ozer-Armon, Chief Executive Officer. "I am particularly excited about the introduction of our new LightSheer(R) line and the Lumenis Pulse(TM)120H, our advanced innovative Urology platform, that we believe will enhance our future growth as they increase our addressable market and improve our position in the industry. The proceeds from our IPO have further solidified our balance sheet and provided capital to further invest in our business."    First Quarter 2014 Financial Results  Total revenue in the first quarter of 2014 was $65.8 million, an increase of 9.5% compared to revenue of $60.1 million last year. Product revenue was $52.6 million, an increase of 11.5% compared to product revenue of $47.2 million last year. Total revenue growth was driven primarily by our two largest business segments, Surgical and Aesthetic and product revenues posted growth in all geographical regions, with particular strength in Europe, the Middle East and Africa (EMEA) and Asia Pacific (APAC).   First quarter 2014 gross profit was $34.6 million, an increase of $3.9 million, or 12.7%, compared to $30.7 million last year. First quarter 2014 gross margin was 52.6%, compared to 51.1% last year, an increase of 151 basis points.   On a GAAP Basis:  First quarter 2014 GAAP oper ating expenses were $33.0 million, an increase of $4.1 million, or 14%, compared to operating expenses of $28.9 million last year. The increase was mainly driven by investment in sales and marketing, increased investment in R&D as well as one-time IPO related expenses.   First quarter 2014 GAAP operating income was $1.6 million, a decrease of $0.1 million, or 8.7%, compared to GAAP operating income of $1.7 million last year. First quarter 2014 GAAP operating margin was 2.4%, compared to 2.9% last year.   First quarter 2014 GAAP net loss was $3.1 million, a decrease of $3.1 million, compared to near breakeven last year. GAAP net loss per share was $0.10 in the first quarter of 2014 compared to breakeven last year, based on 30.9 million and 29.0 million diluted shares outstanding respectively.  On a Non-GAAP Basis:   First quarter of 2014, Non-GAAP results exclude a $4.9 million one-time items related to our IPO. Of these expenses, $4.0 million were a one-time payment to Bank Hapoalim B.M. triggered by the completion of the Company's IPO, as defined in the Company's loan agreement with Bank Hapoalim B.M. Non-GAAP results also exclude stock based compensation expense of approximately $0.8 million and the revaluation income of embedded derivative of approximately $0.3 million.   First quarter 2014 Non-GAAP operating income was $3.3 million, an increase of $1.0 million, or 44.0%, compared to Non-GAAP operating income of $2.3 million last year. First quarter 2014 Non-GAAP operating margin was 5.0%, compared to 3.8% last year.   First quarter 2014 Adjusted EBITDA was $4.8 million, an increase of $1.3 million, or 37.9%, compared to $3.5 million last year. Adjusted EBITDA margin was 7.4% compared to 5.8% last year.   First quarter 2014 Non-GAAP net income was $2.2 million, an increase of $1.3 million, or 154.0%, compared to $0.9 million last year. Non-GAAP net income per diluted share was $0.07 in the first quarter of 2014 compared to $0.03 last year based on 32.4 million and 29.6 million diluted shares outstanding respectively.  Cash and cash equivalents were $114.9 million as of March 31, 2014 compared to $42.8 million as of December 31, 2013. This increase is primarily due to the successful completion of our initial public offering in March 2014.  New Product Introductions and Approvals      --  Surgical: In March, the Company received FDA clearance and CE mark for     the "Lumenis Pulse 120H", the new high-power Holmium platform, offers     an unrivaled combination of power, speed, safety and versatility. This     single platform provides a superior offering for four major urological     procedures -- Enucleation, Flexible Ureteroscopy, Vaporization and     PCNL. The Company is planning over 30 physician training courses     worldwide this year to drive the adoption of this product.           --  Aesthetics: The Company announced two new additions to the     Lightsheer(R) family of hair removal products. The     "Lightsheer(R) Infinity(TM)" is Lumenis' most advanced laser hair     removal system which is an optimal solution for all skin types,     including tanned and dark skin types. The "Lightsheer(R)     Desire(TM)" is a compact, portable and upgradable system with an     advanced user interface, which allows easy treatment delegation and a     quick learning curve. Both systems are up to 75 percent faster than     other currently available devices and have received very positive     feedback from physicians and patients in recent American and European     tradeshows.           --  Ophthalmic: The Company received both an FDA approval and a Japanese     MHLW clearance for the Array(TM) LaserLink(TM) pattern scanning     device for multi-spot laser photocoagulation at the end of calendar     2013, and began commercialization in Japan in the first quarter. The     early market response in Japan for this new scanning device has been     very positive, where Ophthalmologists have expressed enthusiasm     particularly about the shorter treatment time and reduced patient     discomfort.     Full Year 2014 Financial Guidance   For the full year ended December 31, 2014, we expect to report:      --  Revenue in a range of $282 to $285 million, representing an increase     of 6.3% to 7.4% year-over-year --  Adjusted EBITDA in a range of $28.6 to $30.2 million, representing an     increase of 10% to 16% year-over-year --  Non-GAAP Net Income in a range of $17.6 to $19.2 million, representing     an increase of 18% to 29% year-over-year, and Non-GAAP EPS of $0.50 to     $0.54     (1): Net cash flow generated from ongoing business activities includes cash flow from operating and investing activities as well as foreign currency translation adjustments related to cash and cash equivalents in the period.  Conference Call  Lumenis will host a conference call on Monday, May 12, 2014 at 5:00 p.m. Eastern Time to discuss its first quarter 2014 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial the following numbers approximately ten minutes prior to the start of the call: 888-389-5988 for callers based in the United States, 1-80-924-5906 for callers based in Israel and 719-325-2432 for callers  based in all other countries. The reservation code for the call is 9972028. Please dial in approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Lumenis' website at http://www.lumenis.com. The replay will be available on the Company's website for approximately 90 days.  About Lumenis  Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare. For more information visit: www.lumenis.com  Forward-Looking Statements  Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.                                                                                                                   LUMENIS LTD.                                                                 (Unaudited)                                                                                                                                    Consolidated Revenue, by Geography                      ---------------------------------------------------------------------------                                         Three         Three                                                       Months Ended  Months Ended                                                    March 31,     March 31,     % Change                                       ------------- -------------                                                                               Year-over-   U.S. dollars in thousands               2014          2013         Year                                         ------------- ------------- ------------  Revenues:                                                                      Americas                         $      21,545 $      20,579          4.7%   APAC                                    18,755        16,610         12.9%   EMEA                                    14,260        11,403         25.1%   Japan                                   11,244        11,519        -2.4*%                                    ------------- ------------- ------------  Total Revenues                     $      65,804 $      60,111          9.5% (*) +2% on a constant currency basis                                                                                                                                                                                                                         Consolidated Revenue, by Segment                       ---------------------------------------------------------------------------                                         Three         Three                                                       Months Ended  Months Ended                                                    March 31,     March 31,     % Change                                       ------------- -------------                                                                               Year-over-   U.S. dollars in thousands               2014          2013         Year                                         ------------- ------------- ------------  Revenues:                                                                      Aesthetic                        $      26,564 $      21,611         22.9%   Surgical                                24,345        23,202          4.9%   Ophthalmic                              14,895        15,298       -2.6**%                                    ------------- ------------- ------------  Total Revenues                     $      65,804 $      60,111          9.5% (**) -0.8% on a constant currency basis                                                                                                                                                                                                                                                                                                                                                                                          LUMENIS LTD.                                               Condensed Consolidated Statements of Operations                                                (Unaudited)                                                                                     Three          Three                                                      Months Ended   Months Ended                                                   March 31,      March 31,                                                   -------------  -------------  U.S. dollars in thousands (except per share         2014           2013       data)                                                                                                                      -------------  -------------                                                                               Revenues:                                                                                                                                                   Products                                     $      52,606  $      47,198    Services                                            13,198         12,913                                                 -------- -----  -------------  Total Revenues                                 $      65,804  $      60,111                                                                               Cost of Revenues                                                               Products                                            24,688         22,457    Services                                             6,529          6,968                                                 -------------  -------------  Total Cost of Revenues                                31,217         29,425                                                                                                                              -------------  -------------  Gross Profit                                   $      34,587  $      30,686                                                                               Operating Expenses:                                                            Research and development, net                        6,268          5,052    Selling and marketing                               20,861         19,010    General and administrative (*)                       5,872          4,886                                                 -------------  -------------  Total Operating Expenses                              33,001         28,948                                                                                                                              -------------  -------------  Operating Income                               $       1,586  $       1,738                                                                                 Financial expenses, net                                 59            966    IPO related Bank Cash Fee                            4,000              -                                                                                                                              -------------  -------------  Total Financial Expenses                               4,059            966                                                                                                                              -------------  -------------  Pre-Tax Income (Loss)                          $      (2,473) $         772                                                                                 Tax expenses                                           664            814                                                                                                                              -------------  -------------  Net Loss                                       $      (3,137) $         (42)                                                =============  =============                                                                               Net loss per common shares:                                                    Basic                                        $       (0.10) $       (0.00)                                                =============  =============                                                                                 Diluted                                      $       (0.10) $       (0.00)                                                =============  =============                                                                               Weighted-average common shares outstanding:                                    Basic                                           30,865,773     28,981,858                                                 =============  =============                                                                                 Diluted                                         30,865,773     28,981,858                                                 =============  =============                                                                               (*) General and administrative expenses for the three months ended March      31, 2014, include IPO related compensation expenses in the amount of $880.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                LUMENIS LTD.                                                     CONDENSED CONSOLIDATED BALANCE SHEETS                                                                                                                                                                                                                                   March 31,  December 31,                                                     ----------- ------------ (U.S. dollars in thousands)                             2014        2013                                                         ----------- ------------                                                     (Unaudited)              ASSETS                                                                       Cash and cash equivalents                           $   114,869 $     42,811 Trade receivables (net of allowance for doubtful                              accounts of $2,484 and $2,690 at March 31, 2014                              and December 31, 2013 respectively)                     40,896       42,867 Prepaid Expenses and other receivables                    9,770       10,194 Inventories                                              38,058       36,075                                                     ----------- ------------ Total Current Assets                                    203,593      131,947                                                                              Finished goods used in operations, net                    4,756        4,793 Property and equipment, net                               8,795        8,094 Goodwill                                                 50,217       50,217 Severance pay fund                                        3,452        3,875 Other assets                                              7,213        7,519                                                     ----------- ------------ Total Long-Term Assets                                   74,433       74,498                                                     ----------- ------------ TOTAL ASSETS                                        $   278,026 $    206,445                                                     =========== ============                                                                              LIABILITIES AND SHAREHOLDERS' EQUITY                                         Restructured debt                                        17,335       17,493 Trade payables                                           27,095       24,553 Other accounts payable and accrued expenses              43,185       39,413 Deferred revenues and customers advances                 21,312       19,057                                                     ----------- ------------ Total Current Liabilities                               108,927      100,516                                                                              Restructured debt                                        51,489       52,024 Accrued post-employment benefits                          8,428        8,906 Deferred revenues                                         7,765        8,144 Other liabilities                                        19,090       19,155                                                     ----------- ------------ Total Long-Term Liabilities                              86,772       88,229                                                     ----------- ------------                                                                              TOTAL LIABILITIES                                       1 95,699      188,745                                                     =========== ============                                                                              SHAREHOLDERS' EQUITY                                     82,327       17,700                                                     ----------- ------------                                                                                                                                  ----------- ------------ TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY          $   278,026 $    206,445                                                     =========== ============                                                                                                                                                                                                                                                                                                                                                                                                                                  LUMENIS LTD.                                                    Consolidated Statements of Cash Flows                                                     (Unaudited)                                                                                       Three         Three                                                      Months Ended  Months Ended                                                     March 31,     March 31,                                                    ------------  ------------  (U.S. dollars in thousands)                          2014          2013                                                       ------------  ------------                                                                               Cash flows from operating activities:                                        Net Loss                                         $     (3,137) $        (42) Adjustments required to reconcile loss to net                                 cash provided by operating activities:                                      Depreciation and amortization                           1,588         1,252  Compensation related to employees stock option                                plan                                                     794           405  Adjustments related to restructured debt                3,127          (733) Revaluation of financial assets and other, net            296           215  Deferred income taxes, net                                591           655                                                                               Decrease (increase) in trade receivables, net           2,094        (3,172) Decrease (increase) in inventories and finished                               goods used in operations                              (2,700)          864  Increase in prepaid expenses and other                                        receivables                                             (653)          (29) Increase in trade payables                              1,797         4,695  Increase (decrease) in other accounts payables                                and accrued expenses (including short and long-                              term deferred revenues and customer advances)            435           (65) Increase in accrued post-employment benefits,                                 net                                                       38           146  Increase (decrease) in other long term                                        liabilities                                             (267)          499                                                                                                                                ------------  ------------  Net cash provided by operating activities               4,003         4,690                                                                               Cash flows from investing activities:                                        Purchase of property and equipment                       (919)         (638)                                                  ------------  ------------  Net cash used in investing activities                    (919)         (638)                                                                              Cash flows from financing activities:                                        Issuance of share capital, net                         68,852             -  Proceeds from exercise of share options                    35            12                                                   ------------  ------------  Net cash provided by financing activities              68,887            12                                                                               Foreign currency translation adjustments related                              to Cash and cash equivalents                              87          (321)                                                                              Increase in cash and cash equivalents                  72,058         3,743  Cash and cash equivalents at the beginning of                                 the period                                            42,811        27,103                                                                               Cash and cash equivalents at the end of the                                   period                                          $    114,869  $     30,846                                                   ============  ============                                                                               Supplemental information and disclosures of non-                              cash investing and financing activities:                                      Issuance costs by utilizing prepayments        $        311             -                                                   ============  ============    Accrued issuance costs                         $      1,557             -                                                   ============  ============    Purchase of property and equipment             $        650             -                                                   ============  ============     Use of Non-GAAP Financial Measures:   The Company has presented the following non-GAAP financial measures in this press release: non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, adjusted EBITDA and adjusted EBITDA margin. The Company defines non-GAAP operating income as its reported operating income (GAAP) excluding stock-compensation expense, one-time charges and other non-recurring operating costs and expenses. The Company defines adjusted EBITDA as its non-GAAP net income before financial expenses, net, taxes on income, and excluding depreciation and amortization expense. The Company defines its non-GAAP net income to e xclude non-recurring or unusual expenses, specifically, in the first quarter of 2014: (i.) stock based compensation of $0.8 million, (ii.) IPO compensation-related expenses of approximately $0.9 million, (iii.) one-time payment to Bank Hapoalim of approximately $4.0 million triggered by the completion of the Company's IPO and (iv.) embedded derivative revaluation income of approximately $0.3 million in the first quarter of fiscal year 2014.                                                                                                                    LUMENIS LTD.                                                  Reconciliation of GAAP to Non-GAAP results                                                  (Unaudited)                                                                                       Three         Three                                                      Months Ended  Months Ended                                                     March 31,     March 31,                                                    ------------  ------------  (U.S. dollars in thousands)                          2014          2013                                                       ------------  ------------  Reconciliation from GAAP Gross Profit to Non-GAAP Gross Profit                                                                                            GAAP Gross Profit                                $     34,587  $     30,686    Stock-based compensation                                 46            38                                                   ------------  ------------  Non-GAAP Gross Profit                            $     34,633  $     30,724                                                   ============  ============                                                                               Reconciliation from GAAP Operating Income to Non-GAAP Operating Income and    Adjusted EBITDA                                                                                                                                          GAAP Operating Income                            $      1,586  $      1,738    Total stock-based compensation                          793           405    Legal settlements                                         -           120    IPO compensation expenses                               880             -                                                   ------------  ------------  Non-GAAP Operating Income                               3,259         2,263    Depreciation and Amortization                         1,588         1,252                                                   ------------  ------------  Adjusted EBITDA                                  $      4,847  $      3,515                                                   ============  ============                                                                               Reconciliation from GAAP Net Loss to Non-GAAP Net Income                                                                                                  GAAP Net Loss                                    $     (3,137) $        (42)   Total stock-based compensation                          793           405    Legal settlements                                         -           120    IPO compensation expenses                               880             -    One-time payment to Bank Hapoalim BM                  4,000             -    Revaluation of embedded derivative and other                                  non- recurring items                                  (339)          382                                                   ------------  ------------  Non-GAAP Net Income                              $      2,197  $        865                                                   ============  ============                                                                               Reconciliation from GAAP Diluted Net Loss Per Common Share to Non-GAAP        Diluted Net Income Per Common Share                                                                                                                      GAAP diluted net loss per common share           $      (0.10) $      (0.00)                                                  ============  ============  Non-GAAP diluted net income per common share     $       0.07  $       0.03                                                   ============  ============                                                                               Shares used in computing GAAP diluted net income                              per common share                                  30,865,773    28,981,858                                                   ============  ============                                                                               Shares used in computing Non-GAAP diluted net                                 income per common share                           32,356,961    29,604,696                                                   ============  ============      CONTACTS:  For Investor Inquiries: Westwicke Partners  Mark Klausner or Mike Piccinino Tel: +1 (443) 213-0500 lumenis@westwicke.com     
Press spacebar to pause and continue. Press esc to stop.